21 Recruiting Studies Using Pumitamig
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Pumitamig
Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer
📍 UT MD Anderson — Houston, Texas
Non-Small Cell Lung Cancer
View Study & Checklist ➔A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
📍 Karmanos Cancer Institute — Detroit, Michigan
Relapsed/Refractory Small Cell Lung Cancer
View Study & Checklist ➔A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
📍 Local Institution - 0178 — Palo Alto, California
Advanced Renal Cell Carcinoma (RCC)
View Study & Checklist ➔A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
📍 Local Institution - 0170 — Athens, Georgia
Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
View Study & Checklist ➔ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
📍 Highlands Oncology Group — Springdale, Arkansas
Breast Neoplasms
View Study & Checklist ➔Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
📍 Birmingham Hematology and Oncology Associates LLC d/b/a Alabama Oncology — Birmingham, Alabama
Non-small Cell Lung Cancer
View Study & Checklist ➔A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
📍 UCLA Hematology Oncology - Main Site — Los Angeles, California
Non-small Cell Lung Cancer
View Study & Checklist ➔Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
📍 The University of Alabama at Birmingham Hospital — Birmingham, Alabama
Non-small Cell Lung Cancer
View Study & Checklist ➔A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
📍 University of Alabama at Birmingham — Birmingham, Alabama
Lung Cancer
View Study & Checklist ➔A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
📍 Local Institution - 0137 — Duarte, California
Hepatocellular Carcinoma (HCC)
View Study & Checklist ➔Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
📍 ACRC Arizona Clinical Research Center — Tucson, Arizona
Extensive-stage Small-cell Lung Cancer
View Study & Checklist ➔A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
📍 Community Cancer Institute — Clovis, California
Cervical Cancer
View Study & Checklist ➔A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
📍 Yale University — New Haven, Connecticut
Metastatic Colorectal Cancer
View Study & Checklist ➔A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
📍 Local Institution - 0033 — Irvine, California
Solid Tumours
View Study & Checklist ➔A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
📍 Local Institution - 0096 — San Francisco, California
Solid Tumors
View Study & Checklist ➔A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
📍 Southern Cancer Center Pc — Daphne, Alabama
Non-Small Cell Lung Cancer (NSCLC)
View Study & Checklist ➔A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
📍 Mayo Clinic Arizona — Phoenix, Arizona
Advanced Solid Tumor
View Study & Checklist ➔A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
📍 Local Institution - 0428 — Tucson, Arizona
Untreated, Unresectable, or Metastatic Colorectal Cancer
View Study & Checklist ➔A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
📍 Southern Cancer Center Pc — Daphne, Alabama
Non-small Cell Lung Cancer (NSCLC)
View Study & Checklist ➔A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Renal Cell Carcinoma
View Study & Checklist ➔A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
📍 Local Institution - 0284 — Phoenix, Arizona
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
View Study & Checklist ➔